Please use this identifier to cite or link to this item: https://doi.org/10.4161/cbt.13.1.18437
Title: Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells
Authors: Bhattacharya, B. 
Akram, M.
Balasubramanian, I. 
Tam, K.K.Y.
Koh, K.X.
Yee, M.Q.
Soong, R. 
Keywords: 5-Fluorouracil
Combination index
E2F1
PI3-kinase
Thymidylate synthase
Issue Date: 1-Jan-2012
Citation: Bhattacharya, B., Akram, M., Balasubramanian, I., Tam, K.K.Y., Koh, K.X., Yee, M.Q., Soong, R. (2012-01-01). Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biology and Therapy 13 (1) : 74-82. ScholarBank@NUS Repository. https://doi.org/10.4161/cbt.13.1.18437
Abstract: Phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitors are an emerging class of anti-cancer agents. Here, we tested the hypothesis that the dual PI3K/mTOR inhibitor, PI103, could synergize with the chemotherapeutic agent, 5-fluorouracil (5-FU) by inhibiting E2F1, thymidylate synthase (TS) and enhancing DNA damage. Drug combination effects were assessed in gastric cancer cells using the median-effect equation. The specific effects of inhibition of E2F1 and PIK3CA were examined by siRNA, and mTOR by rapamycin exposure. Protein expression and apoptosis pre- and posttreatment was measured using standard methods. PI103 and 5-FU was synergistic in 3 out of 5 gastric cancer cell lines tested. Synergy was associated with PI3KCA mutation, reduced TS and E2F1 protein levels, increased H2AX phosphorylation and apoptosis. E2F1 siRNA enhanced sensitivity to 5-FU only in cells displaying synergy. Excess thymidine exposure converted synergism to antagonismin all cells. Inhibition of PI3K and mTOR alone enhanced 5-FU cytotoxicity in only 2 out of 3 cell lines that displayed synergy each. In AGS cells, PI3K inhibition alone enhanced 5-FU sensitivity as much as dual PI3K/mTOR inhibition. In HGC27 cells, dual inhibition increased 5-FU sensitivity more than single PI3K or mTOR inhibition. Combined PI103 and 5-FU treatment reduced in vivo tumor growth more than treatment with single agents. PI3K/mTOR inhibitors can enhance 5-FU cytotoxicity in vitro and in vivo, especially in PIK3CA mutant tumor cells. Dual, rather than single, PI3K/mTOR inhibitors may combine better with 5-FU due to cellular heterogeneity in sensitivity to PI3K and mTOR inhibition. © 2012 Landes Bioscience.
Source Title: Cancer Biology and Therapy
URI: http://scholarbank.nus.edu.sg/handle/10635/116515
ISSN: 15384047
DOI: 10.4161/cbt.13.1.18437
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

25
checked on Oct 19, 2020

WEB OF SCIENCETM
Citations

24
checked on Oct 19, 2020

Page view(s)

66
checked on Oct 23, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.